Meeting
2019 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guérin (BCG) versus BCG alone in high-risk, BCG-naïve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).
Authors
Maria De Santis
Charité University Hospital, Berlin, Germany
Maria De Santis , Ramil Abdrashitov , Axel Hegele , Margaret Kolb , Suzanne Parker , Juan Palou Redorta , Hiroyuki Nishiyama , Feng Xiao , Ashok Kumar Gupta , Neal D. Shore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT03528694
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS500)
DOI
10.1200/JCO.2019.37.7_suppl.TPS500
Abstract #
TPS500
Poster Bd #
N10
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.
First Author: Tanguy Y. Seiwert
Poster
2022 ASCO Annual Meeting
A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin unresponsive high-risk non-muscle invasive bladder cancer: CREST Study Cohort B.
First Author: Neal D. Shore
Poster
2019 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
First Author: Matt D. Galsky
Poster
2019 ASCO Annual Meeting
Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.
First Author: Ashish M. Kamat